Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan.
Department of Urology, Gifu Prefectural General Medical Center, Gifu 5008717, Japan.
Curr Oncol. 2023 Feb 26;30(3):2792-2800. doi: 10.3390/curroncol30030212.
We aimed to determine whether biochemical recurrence-free survival (BRFS) of patients with prostate cancer (PCa) who received low-dose-rate brachytherapy (LDR-BT) differed according to the definition of biochemical recurrence (BCR) after radical prostatectomy (RP) and the definition given by the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). We reviewed the clinical records of 476 consecutive patients with PCa who received LDR-BT at the Gifu University Hospital. The primary endpoint of this study was the difference in BRFS between the two aforementioned definitions. When the follow-up period ended, 74 (15.5%) and 20 (4.2%) patients had BCR according to the RP and J-POPS definitions, respectively. The 5-year BRFS rates were 85.0% and 96.9% for the RP and J-POPS definitions, respectively ( < 0.005). According to the RP definition, the 5-year BRFS rates were 80.6% in the group aged <63 years and 86.6% in those aged ≥63 years ( = 0.050). According to the J-POPS definition, the 5-year BRFS rates were 94.1% and 97.8% in the groups aged <63 years and ≥63 years, respectively ( = 0.005). The definition of recurrence in LDR-BT may need to be reconsidered.
我们旨在确定接受低剂量率近距离放射治疗（LDR-BT）的前列腺癌（PCa）患者的生化无复发生存率（BRFS）是否因根治性前列腺切除术（RP）后生化复发（BCR）的定义和日本前列腺癌永久性碘-125 种子植入治疗结果研究（J-POPS）的定义而有所不同。我们回顾了在岐阜大学医院接受 LDR-BT 的 476 例连续 PCa 患者的临床记录。本研究的主要终点是这两个定义之间 BRFS 的差异。随访结束时，根据 RP 和 J-POPS 定义，分别有 74 例（15.5%）和 20 例（4.2%）患者发生 BCR。根据 RP 定义，RP 和 J-POPS 定义的 5 年 BRFS 率分别为 85.0%和 96.9%（<0.005）。根据 RP 定义，年龄<63 岁组的 5 年 BRFS 率为 80.6%，年龄≥63 岁组为 86.6%（=0.050）。根据 J-POPS 定义，年龄<63 岁组和年龄≥63 岁组的 5 年 BRFS 率分别为 94.1%和 97.8%（=0.005）。LDR-BT 中复发的定义可能需要重新考虑。
